Got to agree man. The co is in buy

New Post Public Reply Private Reply Replies (0) Message Board
IronPantz

Got to agree man. The co is in buy mode.

http://www.smallcapnetwork.com/Medisafe-1-Tec...d/1/id/87/

Medisafe 1 Technologies Corp. (OTC: MFTH), a development stage company engaged in the development of patented technologies that physically prevent unauthorized administration of prescription medications, announced that it intends to commence its share buyback program at the beginning of March 2012.

MFTH’s Board of Directors had approved a share buyback program last month under which the company has been authorized to repurchase up to 10 million of its outstanding shares of common stock during the next 12 months at a price of up to $0.10 per share on the open market or by conducting privately negotiated transactions depending on the market conditions.

Jacob Elhadad, CEO of Medisafe 1 Technologies, had said last month that the company continues to progress in its efforts to bring further added value to its shareholders. Elhadad had also said that the repurchase of shares will allow MFTH to acquire additional technologies that augment its existing commercial product line.

Last month, Medisafe Technologies had also announced that business development efforts are underway to acquire companies with medical devices and/or lifesaving technologies that are already revenue generating.

Elhadad said last month that MFTH is in the market for companies that have already proven an ability to generate revenues with medical technologies and these technologies will complement MFTH’s patented syringe locking device and transfusion bag locking device that have already proven to be commercially-viable.

Medisafe shares have risen sharply in today’s trading. At last check, the stock was up 45% to $0.0261 on above average volume of 11.96 million. The stock has gained 166.34% in the last three trading sessions.

Medisafe 1 Technolog (MFTH) Stock Research Links

MFTH Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Concerns Rise Over Trump's Cryptocurrency Reserve Strategy

Updated Category News Views 192

Concerns About Cryptocurrency Announcements Prominent economist and market commentator Peter Schiff has urged a Congressional investigation into President Donald Trump's recent foray into cryptocurrency, suggesting that these announcements may involve insider trading and market manipulation. The Key Questions Raised In a recent post on X, Schiff sought answers to several...

Continue Reading
BriaCell Joins Prestigious Program to Boost Cancer Treatments

Updated Category News Views 145

BriaCell Enters MSK’s 2025 Therapeutics Accelerator Program BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ, TSX: BCT) is thrilled to share the news of its selection into the Memorial Sloan Kettering Cancer Center (MSK) Therapeutics Accelerator Program for 2025. This prestigious program is designed to fast-track the clinical development of many innovative cancer...

Continue Reading
Exploring Current Net Asset Values of WisdomTree Funds

Updated Category News Views 114

Understanding Net Asset Value (NAV) in Investment Funds Net Asset Value (NAV) is a crucial metric for evaluating the performance of investment funds, representing the value of a fund's assets minus its liabilities. It's important for investors to keep track of NAV as it aids in making informed decisions regarding their investments. Here, we delve into the recent NAVs of...

Continue Reading
DoorDash's Innovative Tools Transforming Restaurant Dynamics

Updated Category News Views 208

Introduction to DoorDash's Expansion DoorDash (NASDAQ: DASH) has recently unveiled exciting developments regarding its Commerce Platform. This significant enhancement is set to assist restaurants in boosting direct sales while fostering better customer relationships across multiple channels. New Features for Restaurant Success The introduced tools are designed to uplift...

Continue Reading
Mezzion's Udenafil Shows Promise in ADPKD Study

Updated Category News Views 34

Positive News for Udenafil in Kidney Disease New updates from Mezzion Pharma Co., Ltd. have come across quite promising. They've reported some favorable results in a preclinical study of udenafil, targeting autosomal dominant polycystic kidney disease (ADPKD). It appears that this PDE5 inhibitor, typically used in aiding cardiovascular issues, now shows potential in...

Continue Reading